[go: up one dir, main page]

HN2011002809A - Compuestos de vinil indazolilo - Google Patents

Compuestos de vinil indazolilo

Info

Publication number
HN2011002809A
HN2011002809A HN2011002809A HN2011002809A HN2011002809A HN 2011002809 A HN2011002809 A HN 2011002809A HN 2011002809 A HN2011002809 A HN 2011002809A HN 2011002809 A HN2011002809 A HN 2011002809A HN 2011002809 A HN2011002809 A HN 2011002809A
Authority
HN
Honduras
Prior art keywords
vinyl compounds
indazolilo
indazolil
cancer treatment
provides useful
Prior art date
Application number
HN2011002809A
Other languages
English (en)
Inventor
Chen Daohong
yu li Hong
Zhao Genshi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2011002809A publication Critical patent/HN2011002809A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA COMPUESTOS DE VINIL INDAZOLILO UTILES EN EL TRATAMIENYO DE CANCER.
HN2011002809A 2009-05-07 2011-10-21 Compuestos de vinil indazolilo HN2011002809A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17629009P 2009-05-07 2009-05-07
US30141610P 2010-02-04 2010-02-04

Publications (1)

Publication Number Publication Date
HN2011002809A true HN2011002809A (es) 2013-07-22

Family

ID=42238704

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011002809A HN2011002809A (es) 2009-05-07 2011-10-21 Compuestos de vinil indazolilo

Country Status (34)

Country Link
US (1) US8268869B2 (es)
EP (1) EP2427449B1 (es)
JP (1) JP5555314B2 (es)
KR (1) KR101373910B1 (es)
CN (1) CN102421769B (es)
AR (1) AR078411A1 (es)
AU (1) AU2010246114B2 (es)
BR (1) BRPI1013748A2 (es)
CA (1) CA2760535C (es)
CL (1) CL2011002781A1 (es)
CO (1) CO6450624A2 (es)
CR (1) CR20110580A (es)
DK (1) DK2427449T3 (es)
EA (1) EA018149B1 (es)
EC (1) ECSP11011441A (es)
ES (1) ES2408117T3 (es)
HN (1) HN2011002809A (es)
HR (1) HRP20130323T1 (es)
IL (1) IL216004A (es)
JO (1) JO2860B1 (es)
MA (1) MA33244B1 (es)
ME (1) ME01462B (es)
MX (1) MX2011011342A (es)
MY (1) MY160390A (es)
NZ (1) NZ595553A (es)
PE (2) PE20160124A1 (es)
PL (1) PL2427449T3 (es)
PT (1) PT2427449E (es)
RS (1) RS52795B (es)
SG (1) SG175909A1 (es)
SI (1) SI2427449T1 (es)
TW (1) TWI382982B (es)
UA (1) UA104756C2 (es)
WO (1) WO2010129509A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PT2824181T (pt) 2012-03-08 2018-12-20 Astellas Pharma Inc Novo produto de fusão de fgfr3
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2907152A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016105517A1 (en) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
CN105906621A (zh) * 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的乙醇类化合物
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
CN107922349B (zh) * 2015-08-07 2021-05-07 哈尔滨珍宝制药有限公司 作为fgfr和vegfr抑制剂的乙烯基化合物
JP6549311B2 (ja) 2015-08-20 2019-07-24 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． インドール誘導体、その調製方法および医薬におけるその使用
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4056558A4 (en) * 2019-11-06 2023-12-27 Jinan University INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
WO2021138391A1 (en) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022033472A1 (zh) * 2020-08-11 2022-02-17 河南迈英诺医药科技有限公司 Fgfr抑制剂化合物及其用途
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN116554148B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种乙烯基吲唑类氘代fgfr抑制剂药物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AP1666A (en) 2000-09-11 2006-09-29 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors.
JP4383870B2 (ja) * 2001-10-17 2009-12-16 協和発酵キリン株式会社 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
IL164209A0 (en) * 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
JP4093588B2 (ja) 2004-05-26 2008-06-04 ファイザー・インク 新規インダゾール及びインドロン誘導体及び調合剤としてのそれらの使用
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070129364A1 (en) * 2005-12-07 2007-06-07 Han-Qing Dong Pyrrolopyridine kinase inhibiting compounds
EA017852B1 (ru) 2006-12-20 2013-03-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные замещенных индазолов, активные в качестве ингибиторов киназ
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
BRPI0812450A2 (pt) 2007-06-05 2019-09-24 Schering Corp derivados de indazol policíclicos e seu uso como inibidores de erk para o tratamento de câncer
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
WO2009099982A1 (en) * 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors

Also Published As

Publication number Publication date
EA018149B1 (ru) 2013-05-30
CN102421769A (zh) 2012-04-18
HRP20130323T1 (en) 2013-05-31
KR101373910B1 (ko) 2014-03-12
AU2010246114B2 (en) 2012-12-06
DK2427449T3 (da) 2013-04-22
RS52795B (sr) 2013-10-31
AR078411A1 (es) 2011-11-09
SG175909A1 (en) 2011-12-29
CO6450624A2 (es) 2012-05-31
ME01462B (me) 2014-04-20
PL2427449T3 (pl) 2013-08-30
ES2408117T3 (es) 2013-06-18
CA2760535A1 (en) 2010-11-11
TW201105652A (en) 2011-02-16
CL2011002781A1 (es) 2012-05-25
US20100286209A1 (en) 2010-11-11
EA201171367A1 (ru) 2012-04-30
NZ595553A (en) 2013-05-31
EP2427449A1 (en) 2012-03-14
WO2010129509A1 (en) 2010-11-11
MA33244B1 (fr) 2012-05-02
CA2760535C (en) 2014-01-14
MY160390A (en) 2017-03-15
UA104756C2 (uk) 2014-03-11
PE20160124A1 (es) 2016-02-24
AU2010246114A1 (en) 2011-11-03
KR20120004511A (ko) 2012-01-12
PT2427449E (pt) 2013-05-06
JO2860B1 (en) 2015-03-15
JP2012526126A (ja) 2012-10-25
HK1163665A1 (en) 2012-09-14
EP2427449B1 (en) 2013-04-03
BRPI1013748A2 (pt) 2016-04-05
US8268869B2 (en) 2012-09-18
CR20110580A (es) 2012-01-06
PE20120812A1 (es) 2012-07-08
ECSP11011441A (es) 2011-12-30
CN102421769B (zh) 2014-04-02
JP5555314B2 (ja) 2014-07-23
TWI382982B (zh) 2013-01-21
MX2011011342A (es) 2011-11-18
IL216004A (en) 2014-01-30
IL216004A0 (en) 2012-01-31
SI2427449T1 (sl) 2013-05-31

Similar Documents

Publication Publication Date Title
HN2011002809A (es) Compuestos de vinil indazolilo
DOP2011000386A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
UY31432A1 (es) Compuestos de diarilhidantoina
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
BR112012005594A2 (pt) tratamento de câncer
EA201400178A1 (ru) Лечение рака молочной железы
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
MX340259B (es) Formulaciones de testosterona.
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
DK2219683T3 (da) Målrettet radioterapi
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
DK2147122T3 (da) Enzymatisk kræftbehandling
CL2009001973S1 (es) Mostrador.
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
BRPI0912193A2 (pt) compostos terapêuticos.
CY1114071T1 (el) Ενωσεις βινυλοϊνδαζολυλιου
CL2008000274S1 (es) Perfil.
CL2008000265S1 (es) Perfil.
CL2008000275S1 (es) Perfil.
CL2008000276S1 (es) Perfil.
CL2008000262S1 (es) Perfil.
CL2008000260S1 (es) Perfil.
CL2008000267S1 (es) Perfil.
CL2008000258S1 (es) Perfil.